Home/Pipeline/CDC7 Inhibitor

CDC7 Inhibitor

Oncology (Solid Tumors)

PreclinicalActive

Key Facts

Indication

Oncology (Solid Tumors)

Phase

Preclinical

Status

Active

Company

Schrodinger

About Schrodinger

Schrödinger is a computational science pioneer with a dual-business model combining high-margin software licensing with internal drug discovery. Founded in 1990, the company has built a sophisticated, physics-based platform that is widely adopted by pharmaceutical and materials science organizations. Its strategy validates its technology through internal deployment in a therapeutic pipeline, aiming to create diversified revenue streams and capture value across the discovery value chain.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (Solid Tumors) Drugs

Drug	Company	Phase	Status
OATD-02	Molecure	Phase I	Active, recruiting
Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)	Athebio	Pre-clinical	Active Partnership
AB821	Asher Biotherapeutics	Preclinical	Active
Undisclosed Preclinical Pipeline	OncoResponse	Preclinical	Active
Undisclosed Platform Program	Da Zen Theranostics	Pre-clinical	Active
Compound42	Abbmira Therapeutics	Pre-clinical	Active
Clinical Decision Support Service	Curematch	Commercial	Active
CV6-168	CV6 Therapeutics	Phase 1a	Active
Chemophototherapy (CPT)	POP Biotechnologies	Pre-clinical	Active
HRD Testing Solution	SeqOne Genomics	Commercial	Active
Platform Validation & Partnership Development	SingleCell Biotechnology	Pre-clinical	Active
Undisclosed	Y-Trap	Preclinical	Active